AC Immune (ACIU) Net Income towards Common Stockholders (2015 - 2026)
AC Immune (ACIU) posted quarterly Net Income towards Common Stockholders of -$0.19 for Q1 2026, up 9.36% year-over-year from -$0.18 in Q1 2025, and up 99.98% quarter-over-quarter from -$875.12 in Q4 2025.
Powered by 
Analysis
AC Immune (ACIU) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Net Income towards Common Stockholders for 12 consecutive years, with -$0.19 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 9.36% year-over-year to -$0.19; the TTM figure through Mar 2026 stood at -$875.76 (down 50.43% YoY), while the FY2025 annual figure was -$844.29, down 45.02% from the prior year.
- Net Income towards Common Stockholders advanced to -$0.19 in Q1 2026 per ACIU's latest filing, from -$875.12 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $0.07 in Q3 2024 and bottomed at -$19.9 million in Q2 2022.
- Historically, Net Income towards Common Stockholders has averaged -$2.3 million across 5 years, with a median of -$0.25 in 2025.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 122905.79% — and 2024, when it jumped 100.03%.
- AC Immune's Net Income towards Common Stockholders stood at -$881.68 in 2022, then soared by 93.61% to -$56.37 in 2023, then plunged by 932.11% to -$581.78 in 2024, then tumbled by 50.42% to -$875.12 in 2025, then surged by 99.98% to -$0.19 in 2026.
- Business Quant data shows ACIU's Net Income towards Common Stockholders at -$0.19 in Q1 2026, -$875.12 in Q4 2025, and -$0.2 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - | -16.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.45 Mn |
| Mar 31, 2026 | -191.55 |
| Dec 31, 2025 | 70.06 Mn |
| Sep 30, 2025 | -20.00 Mn |
| Jun 30, 2025 | -253.66 |
| Mar 31, 2025 | -21.13 Mn |
| Dec 31, 2024 | 39.95 Mn |
| Sep 30, 2024 | 69.25 |
| Jun 30, 2024 | -25.43 Mn |
| Mar 31, 2024 | -20.62 Mn |
| Dec 31, 2023 | -56.37 |
| Sep 30, 2023 | -203.79 |
| Jun 30, 2023 | -222.44 |
| Mar 31, 2023 | -227.04 |
| Dec 31, 2022 | -238.75 |
| Sep 30, 2022 | -165.67 |
| Jun 30, 2022 | -19.91 Mn |
| Mar 31, 2022 | -19.57 Mn |
| Dec 31, 2021 | 77.00 Bn |
| Sep 30, 2021 | -239.61 |